NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 23 percent, driven in part by sales of its Nanosphere Verigene molecular products, which rose 59 percent over the prior-year quarter to $10.5 million.

For the three months ended March 31, the firm reported revenues of $77.8million, up from $63.0 million a year ago, and beating the consensus Wall Street estimate of $74.2 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.